慢性髓性白血病(CML)是由染色体9和22[t9;22]之间的相互易位引起的费城染色体的存在定义的,该易位产生BCR::ABL1融合基因。慢性粒细胞白血病发生在3个不同的阶段(慢性,加速,和爆炸阶段),通常在发达国家的慢性期被诊断。酪氨酸激酶抑制剂(TKI)治疗是慢性CML患者的高效治疗选择。慢性期CML患者TKI治疗的主要目标是防止疾病进展为加速期CML或急速期CML。在选定的患者中,谨慎监测停止TKI治疗是可行的。本手稿讨论了NCCN指南中概述的慢性CML患者的诊断和管理建议。
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN
Guidelines for the diagnosis and management of patients with chronic phase-CML.